Ardigen's news feed
24 May 2021
Share news in:

Ardigen and OncoArendi join forces for research collaboration

 

Ardigen and OncoArendi join forces for research collaboration

Ardigen, a global leader in artificial intelligence & bioinformatics for precision medicine, and OncoArendi, the company that signed the largest partnering contract in the history of Polish biotechnology in 2020, have announced research cooperation.

Under the terms of this collaboration, Ardigen used the Genetic Reports module of the Gene Regulation Platform to equip OncoArendi with the most comprehensive genetic overview of target genes. Each report gathered comprehensive genetic information on the target gene and contained multiple sections providing genetic information originating from public repositories with enriched commentary.

The Gene Regulation Platform is a suite of powerful machine learning-driven tools for the most efficacious short RNA candidate selection and genetic overview of a target gene. It comprises of: siRNA, miRNA, sgRNA and Genetic Reports modules.

Thanks to this cooperation, OncoArendi will obtain valuable information on genetics and mechanisms of action related to the therapeutic targets under study in the context of selected therapeutic indications. It will also be possible to decide on a potential extension of cooperation with Ardigen, based on additional advanced bioinformatics methods.

About OncoArendi

OncoArendi Therapeutics S.A. is an innovative biotechnology company specializing in the discovery, development and commercialization of new drugs used in the treatment of inflammatory, fibrotic and cancer diseases. OncoArendi Therapeutics’ business model is all about discovery and development of new therapeutic molecules, and then selling the rights to the developed drugs to pharmaceutical companies. The company develops projects for potential first-in-class or best-in-class drugs in their category, which address diseases that currently represent unmet medical needs.

In 2020, OncoArendi successfully completed clinical phase 1 for the drug candidate OATD-01 – a dual chitinase inhibitor. In November 2020, OncoArendi signed the largest cooperation agreement in the history of Polish biotechnology with Galapagos NV with a total biodollar value of over EUR 320 million, which clearly validates the company’s scientific potential and business model. Under the agreement, OncoArendi has granted Galapagos an exclusive license to continue the development of the OATD 01 molecule.

The company has been listed on the GPW since April 2018.

13 May 2021
Assessing off-target toxicity of cellular immunotherapies - CIMT 2021 poster
Go up